Sign up to save your podcasts
Or
Share Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
In this episode, Bernie and Anthony are joined by two special guest expert hematologists:
Dr. David Russler-Germain
Dr. Tycel Phillips
We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?
Stay tuned to find out!
View all episodes
By Bernard Marini, Anthony Perissinotti, et al.
4.5
2828 ratings
In this episode, Bernie and Anthony are joined by two special guest expert hematologists:
Dr. David Russler-Germain
Dr. Tycel Phillips
We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?
Stay tuned to find out!
More shows like WolverHeme Happy Hour
View all
The Hematologist
26 Listeners
JAMA Clinical Reviews
480 Listeners
OncoPharm
183 Listeners
VJHemOnc Podcast
3 Listeners
The Peter Attia Drive
7,765 Listeners
Plenary Session
745 Listeners
Treating Blood Cancers
13 Listeners
Blood Podcast
49 Listeners
Oncology Today with Dr Neil Love
54 Listeners
Healthcare Unfiltered
133 Listeners
EHA Unplugged
2 Listeners
Two Onc Docs
166 Listeners
Blood Cancer Talks
49 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
36 Listeners
HemeTalks: Conversations in Hematology Education
0 Listeners